Mostrando 9 resultados de: 9
Filtros aplicados
Publisher
Pharmacogenomics(4)
Drug Metabolism and Personalized Therapy(2)
Drug Metabolism and Drug Interactions(1)
Neurologia(1)
OMICS A Journal of Integrative Biology(1)
An update on HLA alleles associated with adverse drug reactions
ReviewAbstract: Adverse drug reactions (ADRs) are considered as an important cause of morbidity and mortality. The hPalabras claves:abacavir, adverse drug reactions, Allopurinol, carbamazepine, human leukocyte antigen (HLA), hypersensitivity syndrome, pharmacogenetics, Stevens-Johnson syndromeAutores:Adrián LLerena, Fricke-Galindo I., López-López M.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusInterethnic variability in CYP2D6, CYP2C9, and CYP2C19 genes and pbkp_redicted drug metabolism phenotypes among 6060 ibero-and native Americans: RIBEF-CEIBA consortium report on population pharmacogenomics
ArticleAbstract: Pharmacogenetic variation in Latin Americans is understudied, which sets a barrier for the goal of gPalabras claves:Amerindians, CYP2C19, CYP2C9, CYP2D6, drug metabolism, LATIN AMERICANS, pharmacogenetics, Precision MedicineAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Fcrreiro V., Francisco J.López Hernández, Fricke-Galindo I., Galaviz-Hernandez C., Garza-Ocañas L., Gilman R.H., Gouveia M.H., Grazina M., Humberto Fariñas, Jiménez-Arce G., Jung-Cook H., Lares-Aseff I., Lazalde-Ramos B.P., López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rodrigues-Soares F., Rojas-Martinez A., Santiago Terán, Sarmiento A.P., Scliar M.O., Sosa-Macías M.G., Tarazona-Santos E.M., Tinoco C.A., Zamudio R.Fuentes:googlescopusInterethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)
ReviewAbstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico'sPalabras claves:drug metabolizing enzymes, drug receptors, drug transporters, Mexicans, pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusPharmacogenetics and ethnicity: relevance for clinical implementation, clinical trials, pharmacovigilance and drug regulation in Latin America
Conference ObjectAbstract: Congress of Pharmacogenetics and Personalized Medicine. Ethnicity, clinical implementation and regulPalabras claves:clinical trials, Latin American populations, metabolic genotypes, Metabolic phenotypes, native populations, pharmacogenetics, pharmacovigilanceAutores:Adrián LLerena, Altamirano C., Céspedes-Garro C., Enrique Terán, Francisco J.López Hernández, Galaviz-Hernandez C., Humberto Fariñas, Jung-Cook H., López-López M., MARTHA FORS, Martha M. Fors-López, Moya G.E., Ramirez R., Remírez D., Sosa-Macías M.G., Tarazona-Santos E.M., William F. WatersFuentes:googlescopusPharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
Conference ObjectAbstract: Meeting report of the " Second Symposium on Pharmacology of Cytochrome P450 and Transporters " organPalabras claves:Cytochrome p450, Hispanics, Latin America, pharmacogeneticsAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Doredo P., ElisaAlonso M., Enrique Terán, Estévez-Carrizo F.E., Ferrero V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., García-Mesa M., Garza-Ocañas L., González-Naranjo M.E., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde B., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Remírez-Figueredo D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento-Sánchez A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusPharmacogenetics of adverse reactions to antiepileptic drugs
OtherAbstract: Introduction: Adverse drug reactions (ADRs) are a major public health concern and a leading cause ofPalabras claves:ABCC2, adverse drug reactions, Antiepileptic drugs, CYP2C9, human leukocyte antigen (HLA), pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusRelevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
ArticleAbstract: Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SCPalabras claves:ABCC2, carbamazepine, EPHX1, Epilepsy, NR1I2, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopus